SPOTLIGHT: Sepracor touts data


Sepracor says its experimental therapy for seasonal allergic rhinitis hit its primary and secondary endpoints in a mid-stage trial. Omnaris "demonstrated a statistically significant reduction in 24-hour total nasal symptom scores versus placebo." Release | Report